Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients

Published:2017-04 Issue:2 Volume:27 Page:152-154
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Nguyen Bella H.V.,Kuo James,Budiman Anadian,Christie Hayden,Ali Sayed

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference11 articles.

1. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma;Johnson;J Clin Oncol,2015

2. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma;Shirai;Jpn J Clin Oncol,2016

3. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab;Lau;Muscle Nerve,2016

4. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N Engl J Med,2012

5. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC [Abstract];Antonioa;J Clin Oncol,2015

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel uses of complement inhibitors in myasthenia gravis—Two case reports;Muscle & Nerve;2024-01-11

2. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis;Clinical and Experimental Immunology;2022-11-25

3. Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management;Cureus;2022-10-24

4. : A case report of re-challenge of immune checkpoint inhibitors after immune-related neurological adverse events: Review of literature;Medicine;2022-09-09

5. Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy;Diagnostics;2022-08-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3